Clinical trial
The Standard Versus Prolonged Dual Antiplatelet Therapy After the XINSORB Bioresorbable Scaffold Implantation Trial
NCT04501900 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Standard Versus Prolonged Dual Antiplatelet Therapy After the XINSORB Bioresorbable Scaffold Implantation Trial
- Lead sponsor
- Shanghai Zhongshan Hospital
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- October 31, 2020
- Completion date
- April 30, 2026
- Enrollment
- 2,106 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.